FDA halts Sun Pharma's trials on dermatological drug

The U.S. Food and Drug Administration (FDA) has asked India’s Sun Pharmaceutical Industries Ltd (SUN.NS) to halt tests on one dose of an experimental dermatological drug due to the potential of blood clots, the company said on Tuesday.